Driehaus Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Driehaus Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.2M	Sell	127,562 -28,710	-18%	-$6.44M	0.21%	152
2025 Q4	$33.3M	Sell	156,272 -22,896	-13%	-$4.73M	0.23%	144
2025 Q3	$35.6M	Sell	179,168 -15,940	-8%	-$2.97M	0.26%	132
2025 Q2	$33.7M	Buy	195,108 +43,279	+29%	+$7.05M	0.27%	122
2025 Q1	$23.7M	Buy	151,829 +63,333	+72%	+$9.05M	0.23%	135
2024 Q4	$12.2M	Sell	88,496 -25,818	-23%	-$3.39M	0.1%	224
2024 Q3	$17.1M	Buy	114,314 +32,918	+40%	+$4.45M	0.15%	190
2024 Q2	$11.1M	Sell	81,396 -18,924	-19%	-$2.57M	0.11%	207
2024 Q1	$15.2M	Buy	+100,320	New	+$14.3M	0.15%	196
2023 Q2	–	Sell	-180,234	Closed	-$19.3M	–	393
2023 Q1	$19.3M	Buy	180,234 +7	+0%	+$801	0.27%	120
2022 Q4	$22M	Buy	180,227 +56,887	+46%	+$6.6M	0.33%	98
2022 Q3	$12.7M	Sell	123,340 -14,170	-10%	-$1.34M	0.19%	158
2022 Q2	$12.8M	Buy	137,510 +8,185	+6%	+$771K	0.21%	166
2022 Q1	$15.2M	Buy	129,325 +48,079	+59%	+$5.57M	0.19%	172
2021 Q4	$10.9M	Buy	81,246 +99	+0.1%	+$14.7K	0.11%	229
2021 Q3	$12.9M	Buy	81,147 +24,914	+44%	+$3.41M	0.15%	198
2021 Q2	$7.4M	Buy	56,233 +3,844	+7%	+$512K	0.1%	252
2021 Q1	$6.75M	Sell	52,389 -131,931	-72%	-$20.1M	0.1%	256
2020 Q4	$30.7M	Buy	184,320 +19,219	+12%	+$3.18M	0.5%	56
2020 Q3	$25.5M	Sell	165,101 -21,206	-11%	-$3.05M	0.52%	49
2020 Q2	$27.6M	Buy	186,307 +21,063	+13%	+$2.89M	0.67%	34
2020 Q1	$18.6M	Buy	165,244 +9,832	+6%	+$1.28M	0.62%	42
2019 Q4	$21.6M	Buy	155,412 +12,807	+9%	+$1.42M	0.57%	44
2019 Q3	$13.7M	Sell	142,605 -726	-0.5%	-$81K	0.45%	60
2019 Q2	$16.5M	Sell	143,331 -27,534	-16%	-$3.29M	0.52%	54
2019 Q1	$20.1M	Buy	170,865 +145,451	+572%	+$12.7M	0.76%	29
2018 Q4	$1.59M	Sell	25,414 -24,492	-49%	-$1.54M	0.07%	244
2018 Q3	$3.54M	Buy	49,906 +10,313	+26%	+$710K	0.11%	220
2018 Q2	$2.63M	Sell	39,593 -9,428	-19%	-$620K	0.09%	241
2018 Q1	$3.21M	Buy	+49,021	New	+$2.76M	0.11%	209
2017 Q4	–	Sell	-99,328	Closed	-$3.6M	–	530
2017 Q3	$3.6M	Buy	+99,328	New	+$2.85M	0.14%	192

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Driehaus Capital Management's ASND Position: Q1 2026 in Review

Driehaus Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 18% in Q1 2026, selling an estimated $6.44M and leaving 127,562 shares worth $29.2M. The position accounts for 0.21% of the portfolio, ranked #152.

Driehaus Capital Management first reported a position in ASND in Q3 2017 and has held it in 31 quarters since. The position peaked at $35.6M in Q3 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Driehaus Capital Management held 127,562 shares of Ascendis Pharma A/S worth $29.2M as of Q1 2026.
Driehaus Capital Management sold 28,710 Ascendis Pharma A/S shares in Q1 2026, an estimated $6.44M.
Ascendis Pharma A/S made up 0.21% of Driehaus Capital Management's portfolio in Q1 2026, its #152 holding.
Driehaus Capital Management first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 31 quarters since.
Driehaus Capital Management's Ascendis Pharma A/S position peaked at $35.6M in Q3 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.